AU2021361746A1 - Radioactive complexes of anti-her2 antibody, and radiopharmaceutical - Google Patents

Radioactive complexes of anti-her2 antibody, and radiopharmaceutical Download PDF

Info

Publication number
AU2021361746A1
AU2021361746A1 AU2021361746A AU2021361746A AU2021361746A1 AU 2021361746 A1 AU2021361746 A1 AU 2021361746A1 AU 2021361746 A AU2021361746 A AU 2021361746A AU 2021361746 A AU2021361746 A AU 2021361746A AU 2021361746 A1 AU2021361746 A1 AU 2021361746A1
Authority
AU
Australia
Prior art keywords
antibody
group
peptide
chelating agent
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021361746A
Other languages
English (en)
Other versions
AU2021361746A9 (en
Inventor
Takahisa Hanada
Minoru KAWATANI
Takuya TAKEDA
Gota TONOYA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nihon Medi Physics Co Ltd
Original Assignee
Nihon Medi Physics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nihon Medi Physics Co Ltd filed Critical Nihon Medi Physics Co Ltd
Publication of AU2021361746A1 publication Critical patent/AU2021361746A1/en
Publication of AU2021361746A9 publication Critical patent/AU2021361746A9/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13—Labelling of peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Optics & Photonics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2021361746A 2020-10-16 2021-10-15 Radioactive complexes of anti-her2 antibody, and radiopharmaceutical Pending AU2021361746A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP2020-174840 2020-10-16
JP2020174840 2020-10-16
JP2020215740 2020-12-24
JP2020-215740 2020-12-24
JP2021024688 2021-02-18
JP2021-024688 2021-02-18
PCT/JP2021/038207 WO2022080481A1 (ja) 2020-10-16 2021-10-15 抗her2抗体の放射性複合体、及び、放射性医薬

Publications (2)

Publication Number Publication Date
AU2021361746A1 true AU2021361746A1 (en) 2023-06-22
AU2021361746A9 AU2021361746A9 (en) 2024-06-27

Family

ID=81208085

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021361746A Pending AU2021361746A1 (en) 2020-10-16 2021-10-15 Radioactive complexes of anti-her2 antibody, and radiopharmaceutical

Country Status (10)

Country Link
US (1) US20230390425A1 (cg-RX-API-DMAC7.html)
EP (1) EP4230637A4 (cg-RX-API-DMAC7.html)
JP (1) JPWO2022080481A1 (cg-RX-API-DMAC7.html)
KR (1) KR20230088764A (cg-RX-API-DMAC7.html)
AU (1) AU2021361746A1 (cg-RX-API-DMAC7.html)
CA (1) CA3198721A1 (cg-RX-API-DMAC7.html)
IL (1) IL302111A (cg-RX-API-DMAC7.html)
MX (1) MX2023004428A (cg-RX-API-DMAC7.html)
TW (1) TW202233247A (cg-RX-API-DMAC7.html)
WO (1) WO2022080481A1 (cg-RX-API-DMAC7.html)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
JP6872181B2 (ja) 2015-05-20 2021-05-19 国立大学法人 鹿児島大学 IgG結合ペプチドによる抗体の特異的修飾
DK3470418T3 (da) 2016-06-13 2024-09-30 Univ Kagoshima Site-specifik radioisotop-mærket antistof ved brug af using iggbindende peptid
WO2018230257A1 (ja) 2017-06-16 2018-12-20 国立大学法人鹿児島大学 IgG結合ペプチド、及び該ペプチドによる抗体の特異的修飾
JP2021506842A (ja) * 2017-12-18 2021-02-22 ヤンセン バイオテツク,インコーポレーテツド ポリペプチドの放射性標識
CA3097101A1 (en) * 2018-04-16 2019-10-24 Nihon Medi-Physics Co., Ltd. Modified antibody and radioactive metal-labelled antibody
JP2020021574A (ja) 2018-07-30 2020-02-06 パナソニックIpマネジメント株式会社 光源ユニット、照明器具、及び照明器具用の拡張構造
JP2020174840A (ja) 2019-04-17 2020-10-29 豊丸産業株式会社 遊技機
JP7272895B2 (ja) 2019-08-02 2023-05-12 清水建設株式会社 水平搬送台車
PH12022550894A1 (en) * 2019-10-18 2023-03-27 Nihon Mediphysics Co Ltd Ri-labeled humanized antibody
CN114555132A (zh) * 2019-10-18 2022-05-27 日本医事物理股份有限公司 放射性金属标记抗体的制造方法
JP7680745B2 (ja) 2019-10-24 2025-05-21 国立大学法人 鹿児島大学 1価ccap生成物の製造方法
JP7154465B1 (ja) * 2021-01-08 2022-10-17 日本メジフィジックス株式会社 Ac-225溶液の製造方法およびAc-225溶液を用いた医薬の製造方法
JPWO2023033022A1 (cg-RX-API-DMAC7.html) * 2021-08-31 2023-03-09

Also Published As

Publication number Publication date
IL302111A (en) 2023-06-01
JPWO2022080481A1 (cg-RX-API-DMAC7.html) 2022-04-21
CA3198721A1 (en) 2022-04-21
MX2023004428A (es) 2023-05-04
TW202233247A (zh) 2022-09-01
US20230390425A1 (en) 2023-12-07
EP4230637A1 (en) 2023-08-23
KR20230088764A (ko) 2023-06-20
WO2022080481A1 (ja) 2022-04-21
AU2021361746A9 (en) 2024-06-27
EP4230637A4 (en) 2025-12-17

Similar Documents

Publication Publication Date Title
EP2654803B1 (en) Radiolabeled her2-binding peptide conjugates
US20230094773A1 (en) Ri-labeled humanized antibody
TWI875842B (zh) 放射性金屬標定抗體、其製造方法、螯合連接子、及肽修飾抗體
WO2023277144A1 (ja) Heg1タンパク質に結合するヒト化抗体および当該抗体と放射性核種との複合体
EP4609881A1 (en) Radioactive pharmaceutical composition
EP4328244A1 (en) Humanised antibodies labelled with radionuclides that emit ?-rays
CN116456992A (zh) 抗her2抗体的放射性复合物和放射性药物
US20230390425A1 (en) Radioactive complexes of anti-her2 antibody, and radiopharmaceutical
EP4317188A1 (en) Radioactive complex of anti-egfr antibody, and radiopharmaceutical
EP4480502A1 (en) Radioactive complex of anti-vegf antibody, and radiopharmaceutical
EP4327831A1 (en) Radioactive complex of anti-cd20 antibody, and radiopharmaceutical
EA051630B1 (ru) Радиоактивные комплексы анти-her2 антитела и радиофармацевтическое средство
EP4327833A1 (en) Radioactive antitumor agent
EA050335B1 (ru) Радиоактивный комплекс анти-egfr антитела и радиофармацевтическое средство
HK40092772A (en) Radioactive complexes of anti-her2 antibody, and radiopharmaceutical
CN117377690A (zh) 抗egfr抗体的放射性复合物和放射性药物
CN117769440A (zh) 抗cd20抗体的放射性复合物和放射性药物
EA050695B1 (ru) Способ получения антитела, меченного радиоактивным металлом

Legal Events

Date Code Title Description
SREP Specification republished